Pharmaceuticals News and Research

RSS

IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

Boehringer Ingelheim Pharmaceutical, Inc. today announced initial results of the first 49 people enrolled in the IPF-PRO Registry, which shed light on characteristics of people with IPF at the time of diagnosis.

23 Oct 2015

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Sydney-based, ASX listed, biopharmaceutical company, Medlab Clinical Ltd has been granted ethics approval to progress to two separate human trials using its nanotechnology delivery platform.

23 Oct 2015

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

23 Oct 2015

Breakthrough research suggests that female sex hormone may save lives on the battlefield

Breakthrough research suggests a female sex hormone may be the key to saving lives on the battlefield, where between 2001 and 2011 more than 80 percent of potentially preventable U.S. war injury deaths resulted from blood loss.

22 Oct 2015

New generation of RNAscope products for RNA-biomarker analysis in FFPE tissue released

Advanced Cell Diagnostics Inc. (ACD), the market leader in tissue-based RNA analysis tools for molecular pathology, has announced the release of its next version RNAscope® in situ hybridization (ISH) assay – RNAscope 2.5.

From Advanced Cell Diagnostics 21 Oct 2015

Most drug residues discharged to wastewater come from private households

Most drug residues discharged to wastewater come from private households. As contributors of pollution by Active Pharmaceutical Ingredients (APIs), health establishments, such as hospitals, psychiatric and nursing facilities are hardly worth mentioning.

20 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Honeywell inks definitive agreement to acquire Sigma-Aldrich's laboratory research chemicals business

Honeywell (NYSE: HON) today announced that it has signed a definitive agreement to acquire the Seelze, Germany-based laboratory research chemicals business from Sigma-Aldrich for approximately 105 million euro.

20 Oct 2015

First patients receive doses of antisense drug for Huntington's disease

The first few patients have received doses of an experimental RNA-targeting drug for Huntington's disease, it was announced today.

20 Oct 2015

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

Scientists at The Scripps Research Institute have found a way to change leukemia cells into leukemia-killing immune cells. The surprise finding could lead to a powerful new therapy for leukemia and possibly other cancers.

20 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.

20 Oct 2015

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes.

19 Oct 2015

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.

19 Oct 2015

Allergan completes acquisition of AqueSys

Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.

19 Oct 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

Univfy announces new IVF refund program

At the American Society for Reproductive Medicine Annual Meeting in Baltimore this year, Univfy, the global leader in predictive analytics for in vitro fertilization (IVF), announces a new program to help fertility providers qualify more patients for IVF refund programs.

19 Oct 2015

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Researchers at the Translational Genomics Research Institute joined an international team of scientists in discovering how a protein from malaria could some day help stop cancer.

19 Oct 2015

NYSCF, CBR collaborate to customize creation of high-quality stem cell lines

The New York Stem Cell Foundation and Cbr Systems, Inc. DBA Cord Blood Registry today announced a collaboration to customize the creation of high-quality stem cell lines. NYSCF will create induced pluripotent stem (iPS) cell lines from umbilical cord tissue collected after birth from healthy newborns provided by CBR.

19 Oct 2015

Pharmaceuticals News and Research

IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

New combination treatment approved by FDA for metastatic pancreatic cancer

Breakthrough research suggests that female sex hormone may save lives on the battlefield

New generation of RNAscope products for RNA-biomarker analysis in FFPE tissue released

Most drug residues discharged to wastewater come from private households

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Honeywell inks definitive agreement to acquire Sigma-Aldrich's laboratory research chemicals business

First patients receive doses of antisense drug for Huntington's disease

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Allergan completes acquisition of AqueSys

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Univfy announces new IVF refund program

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

NYSCF, CBR collaborate to customize creation of high-quality stem cell lines

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring